Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Clinical Trials
5
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Not yet recruiting
1
20.0%
Recruiting
2
40.0%
Terminated
2
40.0%
No approval data available
- Telix Pharmaceuticals has signed a strategic agreement to acquire 100% of privately held ITM Isotope Technologies Munich for US$1.65 billion upfront on a cash-free, debt-free basis. - The deal adds up to US$700 million in contingent consideration tied to FDA approvals and sales milestones for ITM-11, a 177Lu-edotreotide therapy for gastroenteropancreatic neuroendocrine tumors. - ITM is the only producer of globally scaled commercial-grade lutetium-177 and supplies radioisotopes across a distribution network spanning more than 65 countries. - ITM-11 has completed the Phase 3 COMPETE trial, while the indication-expansion Phase 3 COMPOSE study is fully enrolled with interim analysis expected in the first half of 2027.
- The FDA approved Telix Pharmaceuticals' Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma in the United States. - Pixclara is indicated to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients aged 1 month and older. - Approval followed an April 2025 Complete Response Letter and a March 2026 resubmission incorporating additional analyses of existing clinical data. - Safety was evaluated in 382 glioma patients, with headache the only adverse reaction occurring in at least 0.5% of patients.
- New publication reveals TLX250-Px (Zircaix®) potential extends beyond its primary indication of clear cell renal cell carcinoma (ccRCC) to other kidney cancer types. - The PET imaging agent demonstrated 86% sensitivity and 87% specificity with 93% positive predictive value for ccRCC in the pivotal Phase 3 ZIRCON trial. - Clinical impact analysis showed 48.6% of patients would have undergone management changes with TLX250-Px imaging compared to standard care. - More than 20% of patients could potentially avoid invasive biopsies when using this carbonic anhydrase IX-targeting diagnostic approach.
- Telix Pharmaceuticals and Regeneron have announced a strategic collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies targeting solid tumors with hard-to-treat cancers. - The partnership combines Telix's radiopharmaceutical development platform and global manufacturing capabilities with Regeneron's antibody discovery technologies, including bispecific antibodies from VelocImmune mice. - Under the agreement, Telix receives $40 million upfront for four initial programs, with potential milestone payments up to $2.1 billion and equal profit-sharing arrangements. - The collaboration will focus on precision oncology applications, including development of radio-diagnostics for patient selection and treatment response assessment in areas of high unmet need like lung cancer.
- Heidelberg Pharma announced a modified licensing agreement with HealthCare Royalty and new partnership with Soleus Capital, securing $20 million upfront and $25 million upon FDA approval of TLX250-Px. - The deal involves partial monetization of future royalties from Telix Pharmaceuticals' imaging diagnostic TLX250-Px, which targets CAIX antigen on clear cell renal cell carcinomas. - Based on current planning and available funds, the agreement ensures company financing through mid-2027, supporting Heidelberg Pharma's ADC development programs. - The company's lead candidate HDP-101 has received FDA Orphan Drug and Fast Track status for multiple myeloma treatment using novel ATAC technology.
- Telix Pharmaceuticals achieved positive Phase 3 results for Illuccix in China, with 94% positive predictive value and 67% of patients experiencing treatment plan changes based on imaging results. - The company dosed its first U.S. patient in the BiPASS Phase 3 trial testing Illuccix and Gozellix alongside MRI for initial prostate cancer diagnosis. - Despite regulatory setbacks with FDA submissions for Pixclara and Zircaix, the company is working through manufacturing and clinical data requirements to advance its pipeline. - Telix shares have declined 56.83% over one year, trading at A$11.48 against analyst price targets of approximately A$25.14, suggesting potential undervaluation.
- Telix Pharmaceuticals announced positive Phase 3 results for TLX591-CDx (Illuccix) in Chinese prostate cancer patients, achieving a 94.8% positive predictive value for tumor detection. - The study of 140 patients with biochemical recurrence demonstrated high accuracy across all PSA levels and metastatic locations, with 67.2% of patients experiencing treatment plan changes. - The company is progressing FDA resubmissions for TLX101-CDx (glioma imaging) and TLX250-CDx (kidney cancer imaging) following productive regulatory meetings. - China represents a strategically important market with over 134,000 new prostate cancer diagnoses in 2022 and expanding PET/CT infrastructure expected to exceed 1,600 cameras by 2025.
- Telix Pharmaceuticals has dosed the first patient in Part 2 of its ProstACT Global Phase 3 study evaluating TLX591, a PSMA-targeted radio antibody-drug conjugate therapy for metastatic castration resistant prostate cancer. - The randomized treatment expansion will enroll approximately 490 patients across multiple countries, representing the first Phase 3 trial to combine a PSMA-targeted rADC therapy with standard of care treatments. - TLX591 demonstrates a differentiated safety profile compared to existing PSMA-targeted therapies, with liver clearance instead of kidney clearance and minimal salivary gland uptake reducing common adverse effects.
- DelveInsight's 2025 assessment reveals a robust prostate cancer pipeline with 140+ companies developing 150+ treatment therapies across various clinical phases. - Recent clinical milestones include Novartis's positive Phase III PSMAddition trial results for Pluvicto combination therapy and MSD-Daiichi Sankyo's initiation of the IDeate-Prostate01 trial for ifinatamab deruxtecan. - Emerging therapies span diverse mechanisms including radioligand therapy, antibody-drug conjugates, and EZH2 inhibitors, with companies like Telix Pharmaceuticals, Pfizer, and AstraZeneca leading development efforts. - The pipeline includes promising late-stage candidates such as 177Lu-DOTA-rosopatamab, mevrometostat, and capivasertib, targeting various stages of prostate cancer progression.
- The Phase 2 OPALESCENCE trial demonstrated TLX250-CDx PET/CT imaging achieved 87.5% overall sensitivity in detecting metastatic triple negative breast cancer lesions. - TLX250-CDx successfully detected all brain metastases confirmed by MRI, while FDG PET/CT detected only one-third of brain lesions. - The study confirms carbonic anhydrase IX expression in TNBC and supports potential theranostic applications for this aggressive cancer subtype. - Results expand TLX250-CDx's clinical utility beyond renal cancer, opening possibilities for lutetium-177 and actinium-225 based therapies.
